Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27870034 | 0.82 | KDM4E (0.43) | ALDH1A1THRBSMN1; SMN2MAPTHTT | |
| SCHEMBL1123625 | 0.79 | KMT2A (0.43) | ALDH1A1MAPK1SMN1; SMN2MAPTHTT | |
| SCHEMBL5694172 | 0.76 | POLB (0.41) | ALDH1A1RAPGEF4THRBSMN1; SMN2HTT | |
| SCHEMBL1123484 | 0.76 | FABP4 (0.47) | ALDH1A1NPSR1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL29101321 | 0.75 | KDM4E (0.57) | ALDH1A1THRBSMN1; SMN2MAPTHTT | |
| SCHEMBL3245827 | 0.75 | POLB (0.42) | ALDH1A1PIK3CATHRBSMN1; SMN2MAPT | |
| SCHEMBL30614582 | 0.75 | HTT (0.43) | ALDH1A1SMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL27668876 | 0.75 | ALDH1A1 (0.37) | ALDH1A1NPSR1THRBSMN1; SMN2GAA | |
| SCHEMBL13490192 | 0.74 | MAPK1 (0.42) | ALDH1A1NPSR1MAPK1RAPGEF4PIK3CD | |
| SCHEMBL9832274 | 0.73 | ALDH1A1 (0.40) | ALDH1A1NPSR1SMN1; SMN2HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125821-A1 | CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN YING BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-04-28 | — | — | US | claimed |
| EP-3087093-B1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2021-11-10 | — | — | EP | claimed |
| EP-3901161-A1 | CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Nankai University (CN) | 2021-10-27 | — | — | EP | claimed |
| CN-112457368-A | Pharmaceutically-related aromatic-cationic peptides | 康德生物医疗技术公司 | 2021-03-09 | — | — | CN | claimed |
| CN-106132984-B | Pharmaceutically-related aromatic-cationic peptides | 康德生物医疗技术公司 | 2020-12-08 | — | — | CN | claimed |
| US-10696716-B2 | Pharmaceutically relevant aromatic-cationic peptides | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-06-30 | — | — | US | claimed |
| US-20200024308-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-01-23 | — | — | US | claimed |
| US-10221213-B2 | Pharmaceutically relevant aromatic-cationic peptides | STEALTH BIOTHERAPEUTICS CORP (MC) | 2019-03-05 | — | — | US | claimed |
| US-20170081363-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2017-03-23 | — | — | US | claimed |
| EP-3114136-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | Stealth BioTherapeutics Corp (MC) | 2017-01-11 | — | — | EP | claimed |
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | FERRER INTERNACIONAL S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-20080303439-A1 | Coating composition for interconnection part of electrode and plasma display panel including the same | SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) | 2008-12-11 | — | — | US | claimed |
| US-20080045694-A1 | Preparation of Solid Phase Bound Peptides or Pnas | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2008-02-21 | — | — | US | claimed |
| EP-1786805-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1749019-A1 | PREPARATION OF SOLID PHASE BOUND PEPTIDES OR PNAS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-02-07 | — | — | EP | claimed |
| WO-2006010756-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S. A. (ES) | 2006-02-02 | — | — | WO | claimed |
| US-20060019366-A1 | Reversibly modified thermostable enzyme compositions and methods of making and using the same | BI WANLI | 2006-01-26 | — | — | US | claimed |
| WO-2005123913-A2 | REVERSIBLY MODIFIED THERMOSTABLE ENZYME COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | NUSTAR LABORATORY (US) | 2005-12-29 | — | — | WO | claimed |
| WO-2005118616-A1 | PREPARATION OF SOLID PHASE BOUND PEPTIDES OR PNAS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2005-12-15 | — | — | WO | claimed |
| US-6153742-A | SOLID PHASE SYNTHESIS PRODUCING ANTISENSE OLIGONUCLEOTIDES | UNIVERSITY OF BARCELONA (ES) | 2000-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200024308-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | ADM2, VIP, ANPEP | ALDH1A1 4716/4885NPSR1 580/4885MAPK1 3212/4885 |
| US-20220125821-A1 | CYCLIC DINUCLEOTIDE PRODRUG MOLECULE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | DPYD, PDE11A, PDE7A | ALDH1A1 1183/4885NPSR1 2336/4885MAPK1 3129/4885 |
| US-10221213-B2 | Pharmaceutically relevant aromatic-cationic peptides | ADM2, VIP, ANPEP | ALDH1A1 4716/4885NPSR1 580/4885MAPK1 3212/4885 |
| US-20170081363-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | ADM2, VIP, ANPEP | ALDH1A1 4618/4885NPSR1 587/4885MAPK1 2803/4885 |
| US-10696716-B2 | Pharmaceutically relevant aromatic-cationic peptides | ADM2, VIP, ANPEP | ALDH1A1 4716/4885NPSR1 580/4885MAPK1 3212/4885 |
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | OXA1L, MAOA, NR0B1 | ALDH1A1 866/4885NPSR1 967/4885MAPK1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.